cnbc.com / .cnbc-com-health-care / Page 2

Investors await earnings from Apple, AMD, and other major companies, as well as the midterm elections and the monthly jobs report.

As young adults denote less wallet share to bars, run clubs, races and recreational leagues become increasingly popular places to build community.

Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.

Coverage of GLP-1 drugs for weight loss is being dropped by many employer-sponsored healthcare plans as premiums soar, though workers have some new options.

The measles resurgence exposes the U.S.' public health weaknesses, such as declining vaccination rates and waning trust in health institutions, experts say.

Looking beyond AI for the next big winner? This drug stock could be headed for a $2 trillion valuation.

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.